One injection: Up to 36 months of continuous treatment
ILUVIEN is a microimplant designed to release a continuous, low-dose treatment to the retina for up to 36 months to help maintain consistent vision longer. The medicine in ILUVIEN is called fluocinolone acetonide (FAc), a type of steroid called a corticosteroid. FAc helps treat the inflammation associated with diabetic macular edema (DME).
During the 3-year clinical trial, 75% of the people treated with ILUVIEN only had 1 ILUVIEN implant.
ILUVIEN may be an option for you if you have been treated for DME before with a prior course of steroid without a clinically significant rise in intraocular pressure (IOP). You may not be a good candidate for ILUVIEN if you have been treated for increased pressure within the eye or glaucoma in the past.
How does ILUVIEN work?
The retina is a thin layer of cells at the back of the eye that captures light and is essential for seeing clearly. The macula is located near the center of the retina and is responsible for central vision. In DME, fluid collects in the macula causing swelling that may lead to blurry vision and vision loss.
ILUVIEN is a corticosteroid used in the treatment of DME.
ILUVIEN is different from other DME treatments. The ILUVIEN microimplant that is inserted into the eye is the only FDA-approved prescription medication for DME that provides continuous treatment for up to 3 years.